Risk of cognitive decline progression is associated to increased blood‐brain‐barrier permeability: A longitudinal study in a memory unit clinical cohort

• Published in: Alzheimer's & dementia Vol. 20; no. 1; pp. 538 - 548
• Main Authors: Puig‐Pijoan, Albert, Jimenez‐Balado, Joan, Fernández‐Lebrero, Aida, García‐Escobar, Greta, Navalpotro‐Gómez, Irene, Contador, Jose, Manero‐Borràs, Rosa‐María, Puente‐Periz, Victor, Suárez, Antoni, Muñoz, Francisco J., Grau‐Rivera, Oriol, Suárez‐Calvet, Marc, Torre, Rafael, Roquer, Jaume, Ois, Angel
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.01.2024; John Wiley and Sons Inc
• Subjects: Alzheimer's disease; Biological markers; Biomarkers; Blood; Blood-Brain Barrier; Brain; Brain research; Cerebrospinal fluid; cerebrovascular disease; cognition; Cognitive ability; Cognitive Dysfunction; Cognitive impairment; Consent; Contraindications; Dementia; Deterioration; Diabetes; Diagnostic tests; Humans; Longitudinal Studies; Magnetic resonance imaging; Male; Medical prognosis; Memory; Movement disorders; Neuropsychology; Observational studies; Patients; Permeability; Proteins; Serum; Sociodemographics; vascular dementia; blood-brain barrier; dementia; cerebrovascular disease; cognition; vascular dementia
• ISSN: 1552-5260; 1552-5279; 1552-5279
• DOI: 10.1002/alz.13433

INTRODUCTION This study examined the relationship between blood‐brain‐barrier permeability (BBBp), measured by cerebrospinal fluid/serum albumin ratio (QAlb), and cognitive decline progression in a clinical cohort. METHODS This prospective observational study included 334 participants from the BIODEGMAR cohort. Cognitive decline progression was defined as an increase in Global Deterioration Scale and/or Clinical Dementia Rating scores. Associations between BBBp, demographics, and clinical factors were explored. RESULTS Male sex, diabetes mellitus, and cerebrovascular burden were associated with increased log‐QAlb. Vascular cognitive impairment patients had the highest log‐QAlb levels. Among the 273 participants with valid follow‐up data, 154 (56.4%) showed cognitive decline progression. An 8% increase in the hazard of clinical worsening was observed for each 10% increase in log‐QAlb. DISCUSSION These results suggest that increased BBBp in individuals with cognitive decline may contribute to clinical worsening, pointing to potential targeted therapies. QAlb could be a useful biomarker for identifying patients with a worse prognosis.